Proof‐of‐concept study to assess the efficacy, safety and tolerability of SAR440340 (anti‐IL‐33 mAb) in patients with moderate‐to‐severe chronic obstructive pulmonary disease (COPD). This evidence concerns the gene IL33 and chronic obstructive pulmonary disease.